---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-002417"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-20T00:40:34.564556+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Pharma Q1 revenue $62.5M, net loss narrows to $0.39; sells olpasiran royalty for $250M

## Summary
- Revenue $62.5M vs $27.4M; net loss $41.3M ($0.39/share) improved from $62.9M ($0.60).
- Total cash and investments $617.6M at Dec 31, up from $482.3M at Sep 30.
- Earned $25M milestone from Amgen for olpasiran Phase 3 start, $15M from Horizon for HZN-457 Phase 1 start.
- Sold olpasiran royalty interest to Royalty Pharma for $250M upfront plus up to $160M contingent payments.
- Topline SEQUOIA study: fibrosis regression in 50% of fazirsiran-treated AATD patients.

## SEC filing metadata
- accession: 0001628280-23-002417
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828023002417/0001628280-23-002417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828023002417/arwr-20230206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-002417
- JSON: https://secwatch.observer/filing/0001628280-23-002417.json
- Plain text: https://secwatch.observer/filing/0001628280-23-002417.txt

## Key facts
- Earnings Releases
  ARROWHEAD PHARMACEUTICALS, INC. reported first quarter ended December 31, 2022 results: revenue $62,546, net income ($41,325), EPS $(0.39).
  - Period: first quarter ended December 31, 2022
  - Revenue: $62,546
  - Net income: ($41,325)
  - EPS: $(0.39)
  - Result: reported results
  source text: INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (in thousands, except per share amounts) Year Ended December 31, OPERATING SUMMARY 2022 2021 (unaudited) Revenue $ 62,546 $ 27,439 Operating Expenses: Research and development 83,695 65,765 General and administrative expenses 20,985 24,995 Total Operating Expenses 104,680 90,760 Operating loss
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828023002417/0001628280-23-002417-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.